BillionToOne, Inc. (BLLN) fair value analysis
Nasdaq · Updated 2026-10-19
BLLN price how computed
Valuation status
Awaiting full valuationBLLN's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once BLLN's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $98.12
- Sector
- Healthcare
- 12-month range
- $64.03–$149.97
- Market cap
- $4.18B
- From 52-week high
- -34.6%
- Shares outstanding
- 42.6M
- Rank in Healthcare by quality score
- #75 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
BillionToOne, Inc. is a healthcare company that develops and commercializes molecular diagnostic technologies designed to detect genetic abnormalities and diseases through advanced DNA sequencing and analysis methods. The company operates in the United States and serves healthcare providers and patients seeking non-invasive prenatal testing and other genetic screening solutions.
BLLN currently ranks #75 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $4.18B
- P/E (trailing)
- 63x
- Revenue (TTM)
- $397M
- Net margin
- 8.4%
- EPS (TTM)
- $1.55
- Gross margin
- 70.5%
- Debt / equity
- 0.27
- Shares outstanding
- 42.6M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 44 · neutral
- 50-day average
- $100.87
- 200-day average
- $95.56
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-04 (post-market)
- Last 4 quarters vs consensus
- 2 beat, 1 missed
- Quarter by quarter
- 2026-06 ▬ met (0.0%)
2026-03 ▲ beat (+3489.0%)
2025-12 ▼ miss (-11.8%)
2025-09 ▲ beat (+468.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 1 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $129
- Target vs last price
- +31.5%
What our data shows for BLLN
- Shares are trading in the middle of their 12-month price range of $64.03–$149.97.
- The 14-day relative strength index sits at a neutral 44.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BLLN's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BLLN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for BLLN showed improvement this week, with the quality grade advancing from C to B. The relative strength index moved from overbought territory into neutral range. The stock's valuation verdict remains awaiting full valuation.
- 2026-10-05 — BLLN in the healthcare sector experienced a shift in its 50/200-day trend state this week, moving from an uptrend to a mixed trend condition. This change in TickrTrends' derived indicators reflects a transition away from the consistent upward momentum that characterized the previous week's technical setup. The valuation assessment for BLLN remains awaiting full valuation at this time.
- 2026-09-28 — TickrTrends' derived indicators for BLLN have shifted this week, with the 50/200-day trend state moving from mixed to uptrend, while the RSI zone has moved from neutral to overbought. The stock currently carries an awaiting full valuation verdict. These changes suggest increased upward momentum in the stock's price movement, though the overbought RSI reading may warrant monitoring for potential consolidation.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BLLN stock undervalued?
BLLN's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is BLLN's TickrTrends verdict?
BLLN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once BLLN's own trailing P/E history validates under our standards.
How does BLLN compare to other Healthcare stocks?
BLLN ranks #75 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BLLN overbought or oversold?
BLLN's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does BLLN report earnings next?
BLLN's next earnings report is scheduled for 2026-11-04 (post-market), per the published earnings calendar.
Does BLLN usually beat earnings estimates?
Over its last 4 reported quarters BLLN beat the consensus estimate 2 times and missed 1 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BLLN?
Of 8 analysts covering BLLN, 7 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $129 (+31.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.